A Post-Actavis Approach To Reverse Payment Settlements
In Federal Trade Commission v. Actavis Inc., the U.S. Supreme Court held that "reverse payment" pharma patent settlements are not categorically immune from the antitrust laws even when within the scope...To view the full article, register now.
Already a subscriber? Click here to view full article